Glucagon as a target for the treatment of Type 2 diabetes
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Glucagon is the key counter-regulatory hormone that opposes the action of insulin. In states of relative hypoglycaemia, glucagon acts to increase blood glucose by stimulating hepatic glycogen breakdown and gluconeogenesis to achieve euglycaemia. Type 2 diabetes is characterised by inappropriate regulation of hepatic glucose production, which is due, at least in part, to an imbalance in the bihormonal relationship between plasma levels of glucagon and insulin. The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia. In recent years, the development of GCGR antisense oligonucleotides and small molecular weight GCGR antagonists have been pursued as possible therapeutic agents to target glucagon action as a treatment for Type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Targets (2005) 9(3) Indeed, a number of studies in humans have demonstrated a positive correlation between hepatic glucose output and fasting plasma glucose levels [8-10].”
BackgroundShah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
ALFORD, F. P., BLOOM, S. R., & NABARRo, J. D. N. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-5-830 · Cited by 74 · cited 1×
“Glucagon acts in a rapid and transient manner with a half-life of minutes in plasma [1].”
BackgroundCompartmental modeling of glucagon kinetics in the conscious dog
Dobbins, R. L., Davis, S. N., Neal, D. W., Cobelli, C., Jaspan, J., & Cherrington, A. D. (1995) · Metabolism · doi:10.1016/0026-0495(95)90051-9 · Cited by 72 · cited 1×
“The kidney and liver appear to be the main sites of glucagon clearance, though reports show a varying contribution of liver to this process and this may be species-dependent [4-6].”
BackgroundLarsson, H., & Ahr�n, B. (1996) · Diabetologia · doi:10.1007/s001250050559 · Cited by 60
Cited by
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Current anti-diabetic agents and their molecular targets: A review
Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.061 · Cited by 369
Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles
Bellina, F., Cauteruccio, S., & Rossi, R. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.02.075 · Cited by 254
Metadata
- Authors
- Sloop, K. W., Michael, M. D., & Moyers, J. S.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2005-06
- Volume
- 9
- Issue
- 3
- Pages
- 593-600
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2053963792
- Cited by
- 63
- References
- 7
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon as a target for the treatment of Type 2 diabetes. https://app.cochat.ai/papers/10.1517/14728222.9.3.593
- The paper
- Sloop, K. W., Michael, M. D., & Moyers, J. S. (2005). Glucagon as a target for the treatment of Type 2 diabetes. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.9.3.593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.